Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198800 | 0.94 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL12662215 | 0.94 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL1199298 | 0.94 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL14380267 | 0.86 | CXCR2 (0.78) | CXCR2CX3CR1 | |
| SCHEMBL1197995 | 0.83 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL12843897 | 0.83 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL1199471 | 0.82 | CXCR2 (1.00) | CXCR2CX3CR1 | |
| SCHEMBL12844086 | 0.82 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL1198248 | 0.82 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL12844098 | 0.82 | CXCR2 (1.00) | CXCR2CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2009992-B1 | IL-8 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2012-06-27 | — | — | EP | claimed |
| US-20110059937-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION | 2011-03-10 | — | — | US | claimed |
| US-20090093451-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-09 | — | — | US | claimed |
| EP-2009992-A2 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2007124424-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-01 | — | — | WO | claimed |
| EP-2009992-B1 | IL-8 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2009992-B1 | IL-8 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20110105563-A1 | IL-8 RECEPTOR ANTAGONISTS | BUSCH-PETERSEN JAKOB | 2011-05-05 | — | — | US | disclosed |
| US-20110105563-A1 | IL-8 RECEPTOR ANTAGONISTS | BUSCH-PETERSEN JAKOB | 2011-05-05 | — | — | US | disclosed |
| US-20110059937-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION | 2011-03-10 | — | — | US | disclosed |
| US-20110059937-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION | 2011-03-10 | — | — | US | disclosed |
| US-7893089-B2 | IL-8 receptor antagonists | GlaxoSmithKline, LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090093451-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093451-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-09 | — | — | US | disclosed |
| EP-2009992-A2 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007124424-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007124424-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249672-A1 | IL-8 Receptor Antagonists | GLAXOSMITHKLINE LLC | 2007-10-25 | — | — | US | disclosed |
| US-20070249672-A1 | IL-8 Receptor Antagonists | GLAXOSMITHKLINE LLC | 2007-10-25 | — | — | US | disclosed |
| US-20070249672-A1 | IL-8 Receptor Antagonists | GLAXOSMITHKLINE LLC | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105563-A1 | IL-8 RECEPTOR ANTAGONISTS | CXCL8, CCR8, IL1RN | CXCR2 12/4885CX3CR1 33/4885 |
| US-20070249672-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | CXCR2 12/4885CX3CR1 33/4885 |
| US-20110059937-A1 | IL-8 RECEPTOR ANTAGONISTS | CXCL8, CCR8, IL1RN | CXCR2 12/4885CX3CR1 33/4885 |
| US-20090093451-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | CXCR2 12/4885CX3CR1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.